Compare PARR & INDV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PARR | INDV |
|---|---|---|
| Founded | 1984 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Integrated oil Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.7B |
| IPO Year | 2000 | 2014 |
| Metric | PARR | INDV |
|---|---|---|
| Price | $64.62 | $30.39 |
| Analyst Decision | Hold | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $57.00 | N/A |
| AVG Volume (30 Days) | 1.5M | ★ 3.4M |
| Earning Date | 05-05-2026 | 06-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 1313.56 | ★ 8100.00 |
| EPS | ★ 7.16 | 1.64 |
| Revenue | ★ $2,443,066,000.00 | $1,239,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.73 | N/A |
| P/E Ratio | ★ $9.06 | $18.58 |
| Revenue Growth | ★ 30.99 | 4.29 |
| 52 Week Low | $12.17 | $8.67 |
| 52 Week High | $66.75 | $38.00 |
| Indicator | PARR | INDV |
|---|---|---|
| Relative Strength Index (RSI) | 68.15 | 46.18 |
| Support Level | $34.55 | $29.71 |
| Resistance Level | N/A | $35.75 |
| Average True Range (ATR) | 3.56 | 1.27 |
| MACD | 0.08 | 0.17 |
| Stochastic Oscillator | 85.18 | 59.43 |
Par Pacific Holdings Inc is an oil and gas company that manages and maintains interests in energy and infrastructure businesses. The company has three reportable segments: Refining. Under its refining business, the company produces ultra-low-sulfur diesel, gasoline, jet fuel, marine fuel, LSFO, and other associated refined products. Its Retail includes operating licenses out brands to serve the retail consumer. Through the Logistics segment, crude shipments are delivered to the refineries, in addition to finished products that are exported. It generates maximum revenue from the Refining segment.
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).